To test this concept, we interrogated the TRACERx study, which utilizes multiregion exome sequencing to determine clonal evolutionary processes during tumor development in human nonsmall cell lung cancer of which 50–70% display aberrant PI3K/AKT/mTORC1 activation [37, 38]. The gene discussed is PIK3CA; the disease is lung cancer.